The early manifestation, tumor-specific occurrence and prognostic significance of TGFBR2 aberrant splicing in oral carcinoma.
Alternative splicing is an important mechanism that can disrupt cell cycle control resulting in tumorigenesis. Although many alterations of Transforming Growth Factor Beta (TGFβ) signaling are reported in cancers, the role of splice aberrations in destabilizing this signaling is the least understood mechanism. In this study, we compared TGFBR2 alternative splicing events in potentially malignant oral disorders (PMDs) and oral squamous cell carcinoma (OSCC) samples with those in normal samples. Interestingly, there were five alternatively spliced forms of TGFBR2 with a deficient kinase domain in OSCCs. The TGFBR2 aberrant splicing was tumor-specific, suggesting that selective splicing out of TGFBR2 kinase domain could be a mechanism misused by cancer cells for evading TGFβ signaling-mediated anti-tumor activities. Moreover, these aberrant transcripts were present in PMDs as well, suggesting an early occurrence of these events during oral carcinogenesis and offering the possibility of early diagnosis of malignancy. Furthermore, OSCC patients who harbored these aberrantly spliced transcripts exhibited poor disease free survival (p=0.028) and poor overall survival (p=0.013). Thus, assessing the presence of these TGFBR2 transcripts can serve as a prognostic marker for oral cancer.
Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India.
V P
VP
Sivadas
Department of Oral Medicine and Radiology, Govt. Dental College, Kozhikode, Kerala, India.
Saakshi
S
Gulati
Division of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India.
Bipin T
BT
Varghese
Department of Oral Medicine and Radiology, Govt. Dental College, Kozhikode, Kerala, India.
Anita
A
Balan
Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India. Electronic address: kannans@rcctvm.gov.in.
S
S
Kannan
D017398:Alternative Splicing / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics; D063646:Carcinogenesis / Q000235:genetics / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D018572:Disease-Free Survival; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D020014:K562 Cells; D007624:KB Cells; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*
D014408:Biomarkers, Tumor; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II
Alternative splicing; Kinase domain; Oral cancer; Sequencing; TGFBR2; TGFβ signaling